drugset / Trial / NCT05017610

Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma

NCT05017610

NaSingle-groupOpen-labelTreatment

Summary

This early phase I trial studies the safety and feasibility of inducing a hypothyroxinemic state in patients with glioblastoma or gliosarcoma that has come back (recurrent). This trial aims to see if giving a specific thyroid hormone, such as methimazole and liothyronine, is safe and could benefit cancer treatment.

Timeline

Start
2021-10-20
Primary completion
2022-10-14
Completion
2022-10-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Liothyronine Small molecule Oral
Subject Lomustine Small molecule Oral
Subject Methimazole Small molecule Oral

Indications